Windt Le Grand Leeuwenburgh Advocaten

European Commission and national competition authorities are pushing back against abuse of dominance in the pharmaceutical sector and high medicine prices

On 10 February 2021 the European Commission accepted commitments offered by pharmaceutical producer Aspen for price reductions for 6 critical cancer medicines. This brought an end to the Commission’s investigation under Article 102 TFEU (abuse of a dominant position) into Aspen’s pricing practices, which it had started in 2017. The investigation concerned Aspen’s pricing policy for its medicines, which are used in the treatment of certain types of cancer such as leukaemia and other haematological cancers.

Read the full article here

About this post

Date: 18 March 2021
Published on: Lexology

Also interesting